RxDoctor Payments Data

Jennifer Stayton, APRN

Nurse Practitioner · North Charleston, SCNPI 1841913845

Payments from drug & device makers

$5,257in general payments, 2019–2025

Across 278 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$764
  • Sanofi-aventis U.S. LLC$401
  • Lilly USA, LLC$327
  • Cardiva Medical, Inc.$283
  • Pfizer$264
  • Corium, LLC$264
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,257 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$21,137
Medicare patients
55
Services billed
750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$22,993
MounjaroTirzepatide20$22,027
FarxigaDapagliflozin Propanediol12$11,435
Albuterol Sulfate HfaAlbuterol Sulfate32$974
Allopurinol18$766
Rosuvastatin Calcium55$560
Levothyroxine Sodium53$548
Fluticasone Propionate34$536
Gabapentin22$460
Pravastatin Sodium22$450
Losartan Potassium53$382
Omeprazole29$345
Colchicine12$324
Ezetimibe34$319
Amlodipine Besylate75$300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$250$22,99320 claims
Lilly USA, LLCMounjaro$327$22,02720 claims
AstraZenecaFarxiga$100$11,43512 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$40$54853 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in North Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →